

ISSN Print: 2664-6781
ISSN Online: 2664-679X
Impact Factor: RJIF 5.32
IJACR 2024; 6(1): 01-04
www.chemistryjournals.net
Received: 03-11-2023
Accepted: 05-12-2023

Dr. Amit Anand
Assistant Professor,
Department of Chemistry G.D. College Begusarai, Bihar, India

Corresponding Author:
Dr. Amit Anand
Assistant Professor,
Department of Chemistry G.D. College Begusarai, Bihar, India

Analysis of challenges and applications of recent advances in drug discovery

Dr. Amit Anand

DOI: https://doi.org/10.33545/26646781.2024.v6.i1a.161

Abstract
This research article provides a comprehensive overview of the recent advances, challenges, and applications in drug discovery, emphasizing the integration of multidisciplinary approaches from target identification to clinical application. With a focus on emerging technologies, computational methods, and evolving paradigms, this article aims to shed light on the dynamic landscape of drug discovery and its potential to transform healthcare. Drug discovery is the process of identifying and characterizing molecules that can safely modulate disease. The goal is to bring medicines that can improve the lives of patients. Drug discovery and development are the most important translational science activities that advance human health and well-being. The main goal of Drug discovery campaigns is to identify new molecular entities that may be valuable in the treatment of diseases that meet unmet medical needs. It is a long and resource-intensive process that requires close collaboration between several disciplines. Optimizing the Drug discovery process is of great interest to the pharmaceutical industry, because the effective identification and selection of suitable drug candidates can have a dramatic impact on the cost and profitability of new drugs, as well as factors affecting drug, pharmacodynamic and drug balance Pharmacokinetic properties. Drug discovery is a risky and rewarding business that requires a multidisciplinary approach. An optimal Drug discovery unit integrates the science of various functions, including chemistry, biology, clinical science and toxicology. Because computational approaches are an integral part of interdisciplinary drug development, it is important to understand the tools used and their potential and limitations. In the current scenario, researchers apply a wide range of computational approaches, with a special focus on medicinal chemistry and Drug discovery and their practical applications. Here, current trends in computational chemistry and computer-aided Drug discovery can accelerate the Drug discovery process.

Keywords: Drug discovery, computational approach, pharmacodynamic, pharmacokinetic, human health

Introduction
This article reviews key developments that shape the landscape of drug discovery and explores their applications in translational medicine. Modern drug discovery research started to being performed around the early 1900s. The drug discovery process is a complex journey that begins with the identification of promising biological targets and culminates in the development of effective and safe therapeutic agents. It involves a series of systematic steps that span from target identification and validation to the development of marketable drugs. The process typically encompasses interdisciplinary collaboration among scientists, including chemists, biologists, pharmacologists, and clinicians. Recent years have witnessed remarkable progress in various facets of drug discovery, driven by advances in genomics, high-throughput screening, artificial intelligence, and our deeper understanding of molecular and cellular processes.

Aim of study
This research article provides a comprehensive overview of the recent advances, challenges, and applications in drug discovery, emphasizing the integration of multidisciplinary approaches from target identification to clinical application. With a focus on emerging technologies, computational methods, and evolving paradigms, this article aims to shed light on the dynamic landscape of drug discovery and its potential to transform healthcare.

Literature review

(Brogi and Calderone, 2021; Ruffolo *et al*., 2021; Jayatunga *et al*., 2022; Sadybekov and Katritch, 2023) [1, 12, 6, 13]. Artificial Intelligence (AI or indeed, most of the time, machine learning) can definitely contribute here as it involves the use of powerful computers and efficient program algorithms to integrate large volume of data to train expert systems to perform a complex task According to (Lambert, 2010; Gupta *et al*., 2021; Paul *et al*., 2021; Kontoyianni, 2022; Vijayan, *et al*., 2022) [9, 3, 11, 8, 14]. During the early discovery phases, AI is used to rationalize processes, and to assist in project management (e.g., definition of a target product profile that allows to locate each compound with regard to the expected final drug specifications in a complex multi-dimensional space), to summarize information, to understand better complex biological systems (e.g., using for instance system biology and chemogenomics approaches), or to propose original compounds or biologics (e.g., small molecules, peptides) generated by the machine under various types of constraints (e.g., ADMET constraints or affinity to the target). (DiMasi, 2020) [2] Reported that the cost to develop a new drug is very high, in part because failure is endemic in drug discovery, and success is rare. While various numbers have been reported, the latest formal assessment is around US $2.8 billion (DiMasi, 2020) [2]. Clinical studies in humans can then get started to establish safety and efficacy of the drugs in patients with the highest benefit-to-risk ratio (Kandi and Vadakedath, 2023) [7].

Methodology

Nowadays, the development of a new medicine usually starts when basic research, often performed in academia, identifies a macromolecule (i.e., a molecule with a large molecular weight like genes/proteins), or a dysfunctional signaling pathway or a molecular mechanism apparently linked to a disease condition (Pre-discovery stage). (Hefti, 2008; Hughes *et al*., 2011; Mohs and Greig, 2017; Villoutreix, 2021) [4, 5, 10, 15].

The key stages in the drug discovery process

Target identification and validation

1. **Target identification:** This step involves identifying specific molecules or biological processes (targets) that play a crucial role in the development or progression of a disease. These targets can be proteins, nucleic acids, or other molecules.
2. **Target validation:** Once a potential target is identified, it undergoes validation to ensure its relevance and importance in the disease. This often involves genetic and molecular techniques to confirm the target's role.

Hit discovery

- **High-throughput screening (HTS):** Researchers screen large libraries of compounds to identify potential hits-molecules that show some activity gainst the chosen target. HTS allows for the rapid testing of thousands to millions of compounds.
- **Virtual Screening:** Computational methods are employed to predict the likelihood of certain compounds binding to the target, reducing the number of compounds that need to be experimentally tested.

Hit-to-lead optimization

- **Medicinal Chemistry:** The hits are further developed into lead compounds through iterative cycles of chemical modification to enhance their potency, selectivity, and other pharmacological properties.
- **ADME/Tox assessment:** Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME/Tox) studies help evaluate how well a compound is absorbed, distributed, metabolized, and excreted, as well as its potential toxic effects.

Lead optimization

Further optimization: The most promising lead compounds undergo further optimization to improve their efficacy and safety profiles. This involves fine-tuning their chemical structures based on iterative testing and analysis.

Preclinical development

- **Animal studies:** Lead compounds are tested in animal models to assess their safety, efficacy, and potential side effects before advancing to human clinical trials.
- **Regulatory approval:** Regulatory agencies review preclinical data to determine if the compound is safe for testing in humans.

Clinical development

- **Clinical trials:** The compound undergoes three phases of clinical trials to evaluate its safety, efficacy, and optimal dosage in human subjects. These phases involve increasing numbers of participants and are conducted under strict regulatory oversight.
- **Regulatory approval:** Positive clinical trial results are submitted to regulatory agencies for approval to market the drug.

Post-Market Surveillance

Post-Marketing Studies: After a drug is approved, ongoing surveillance and studies monitor its long-term safety and effectiveness in larger patient populations.

Rising cost: from drug discovery to new treatments

The cost to develop a new drug is very high, in part because failure is endemic in drug discovery, and success is rare. While various numbers have been reported, the latest formal assessment is around US $2.8 billion (DiMasi, 2020) [2]. The drug discovery process is time-consuming, expensive, and often involves a high rate of attrition. Advances in technologies such as genomics, proteomics, and artificial intelligence have contributed to improving the efficiency and success rate of drug discovery efforts.

Result & discussion

Drug discovery applications: Drug discovery applications span a wide range of scientific disciplines and technologies, each contributing to the overall process of identifying and developing new therapeutic compounds. Here are some key applications and technologies in drug discovery:

Computational biology and bioinformatics

1. **Virtual Screening:** Computational methods are used to simulate the interaction between potential drug molecules and target proteins. This helps in predicting the likelihood of a compound binding to a target and guides experimental screening efforts.

2. **Structural bioinformatics:** Understanding the three-dimensional structures of biological molecules aids in rational drug design by identifying potential binding sites and optimizing ligand-receptor interactions.

High-Throughput screening (HTS)
- **Automation:** HTS involves the rapid testing of thousands to millions of compounds for their biological activity. Automated systems and robotics streamline this process, allowing for increased efficiency and throughput.
- **Assay development:** Designing and optimizing assays that accurately measure the activity of a compound against a specific target is crucial for successful HTS campaigns.

Medicinal chemistry
- **Structure-activity relationship (SAR) Studies:** Medicinal chemists analyze the relationship between the chemical structure of compounds and their biological activity. This information guides the optimization of lead compounds.
- **Combinatorial chemistry:** Techniques that generate large libraries of diverse chemical compounds enable the rapid synthesis and testing of a wide range of potential drug candidates.

Genomics and functional genomics
- **Target identification:** Genomic data is used to identify potential drug targets by understanding the genetic basis of diseases.
- **CRISPR/Cas9 technology:** Gene editing tools like CRISPR allow researchers to selectively modify genes to validate targets and study their role in diseases.

Pharmacogenomics
- **Personalized medicine:** Pharmacogenomics considers individual genetic variations to predict responses to drugs, allowing for the development of personalized treatment plans.
- **Biomarker discovery:** Identifying biomarkers associated with disease or drug response helps in patient stratification and monitoring treatment efficacy.

Systems biology
- **Network pharmacology:** Understanding the complex interactions within biological systems helps in identifying multiple targets for drug development, considering the interconnectedness of pathways.
- **Integration of Omics Data:** Combining data from genomics, transcriptomics, proteomics, and metabolomics provides a comprehensive view of biological systems and aids in drug discovery.

Bioanalytical techniques
- **Mass Spectrometry and NMR:** These techniques are used for the structural elucidation of compounds, including the identification of metabolites and the study of drug metabolism.
- **X-ray crystallography and cryo-electron Microscopy:** These methods help in determining the three-dimensional structures of biological macromolecules, facilitating structure-based drug design.

Artificial intelligence (ai) and machine learning:
- **Drug repurposing:** AI analyzes existing drug databases and biomedical literature to identify potential new uses for existing drugs.
- **Predictive modeling:** Machine learning models predict the pharmacological properties and safety profiles of compounds, aiding in lead optimization. (Brogi and Calderone, 2021; Ruffolo *et al*., 2021; Jayatunga *et al*., 2022; Sadybekov and Katritch, 2023) [1, 12, 6, 13].

Chemo informatics
- **Chemical database mining:** Analyzing large chemical databases helps in identifying existing compounds with potential therapeutic effects.
- **Chemical similarity searches:** Identifying structurally similar compounds to known drugs can guide the discovery of new drug candidates.

These applications collectively contribute to the drug discovery pipeline, making the process more efficient, cost-effective, and capable of addressing the complexities of various diseases. Interdisciplinary collaboration and the integration of these technologies are key to advancing drug discovery efforts.

Challenges and opportunities
- Identification of challenges in drug discovery, including high attrition rates, cost considerations, and the need for improved translatability from preclinical to clinical studies.
- Opportunities for collaboration, open science initiatives, and public-private partnerships to address the complex challenges in drug development.

Conclusion

This review provides a snapshot of the diverse and dynamic landscape of drug discovery literature, emphasizing the integration of various disciplines and technologies to accelerate the development of innovative and effective therapeutic interventions. Drug discovery is undergoing a transformative phase, driven by innovation, collaboration, and technological advancements. This article has provided a glimpse into the recent progress, challenges, and future directions in drug discovery, highlighting its pivotal role in advancing medical science and improving patient outcomes. As researchers continue to push the boundaries of knowledge, the synergy between diverse disciplines will be instrumental in bridging the gap from bench to bedside.

References

1. Brogi S, Calderone V. Artificial intelligence in translational medicine. Int J Transl Med. 2021;1:223–285. doi:10.3390/ijtm1030016.
2. DiMasi JA. Research and development costs of new drugs. JAMA. 2020;324:517. doi:10.1001/jama.2020.8648.
3. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta R, Kumar P. Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Mol Divers. 2021;25:1315–1360. doi:10.1007/s11030-021-10217-3.
4. Hefti FF. Requirements for a lead compound to become a clinical candidate. BMC Neurosci. 2008;9(S7). doi:10.1186/1471-2202-9-S3-S7.

5. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162:1239–1249. doi:10.1111/j.1476-5381.2010.01127.x.
6. Jayatunga MKP, Xie W, Ruder L, Schulze U, Meier C. AI in small-molecule drug discovery: A coming wave? Nat Rev Drug Discov. 2022;21:175–176. doi:10.1038/d41573-022-00025-1.
7. Kandi V, Vadakedath S. Clinical trials and clinical research: A comprehensive review. Cureus. 2023;15:e35077. doi:10.7759/cureus.35077.
8. Kontoyianni M. Library size in virtual screening: Is it truly a numbers game? Expert Opin Drug Discov. 2022;17:1177–1179. doi:10.1080/17460441.2022.2130244.
9. Lambert W. Considerations in developing a target product profile for parenteral pharmaceutical products. AAPS Pharm Sci Tech. 2010;11:1476–1481. doi:10.1208/s12249-010-9521-x.
10. Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimers Dement (NY). 2017;3:651–657. doi:10.1016/j.trci.2017.10.005.
11. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade R. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26:80–93. doi:10.1016/j.drudis.2020.10.010.
12. Ruffolo JA, Sulam J, Gray JJ. Antibody structure prediction using interpretable deep learning. Patterns (N Y). 2021;3:100406. doi:10.1016/j.patter.2021.100406.
13. Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature. 2023;616:673–685. doi:10.1038/s41586-023-05905-z.
14. Vijayan RSK, Kihlberg J, Cross JB, Poongavanam V. Enhancing preclinical drug discovery with artificial intelligence. Drug Discov Today. 2022;27:967–984. doi:10.1016/j.drudis.2021.11.023.
15. Villoutreix BO. Post-pandemic drug discovery and development: Facing present and future challenges. Front Drug Discov. 2021;1. doi:10.3389/fddsv.2021.728469.